BMS Trumpets Breakthrough For Phase III-Bound IPF Drug

Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.